Literature DB >> 27792871

Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease.

Jane C Burns1, Isabelle Koné-Paut2, Taco Kuijpers3, Chisato Shimizu1, Adriana Tremoulet1, Moshe Arditi4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27792871      PMCID： PMC5274552          DOI： 10.1002/art.39975

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN： 2326-5191            Impact factor:   10.995


× No keyword cloud information.
  75 in total

1.  Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease.

Authors:  Chiea Chuen Khor; Sonia Davila; Willemijn B Breunis; Yi-Ching Lee; Chisato Shimizu; Victoria J Wright; Rae S M Yeung; Dennis E K Tan; Kar Seng Sim; Jie Jin Wang; Tien Yin Wong; Junxiong Pang; Paul Mitchell; Rolando Cimaz; Nagib Dahdah; Yiu-Fai Cheung; Guo-Ying Huang; Wanling Yang; In-Sook Park; Jong-Keuk Lee; Jer-Yuarn Wu; Michael Levin; Jane C Burns; David Burgner; Taco W Kuijpers; Martin L Hibberd
Journal:  Nat Genet       Date:  2011-11-13       Impact factor: 38.330

2.  Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes.

Authors:  Cailin H Sibley; Nikki Plass; Joseph Snow; Edythe A Wiggs; Carmen C Brewer; Kelly A King; Christopher Zalewski; H Jeffrey Kim; Rachel Bishop; Suvimol Hill; Scott M Paul; Patrick Kicker; Zachary Phillips; Joseph G Dolan; Brigitte Widemann; Nalini Jayaprakash; Frank Pucino; Deborah L Stone; Dawn Chapelle; Christopher Snyder; John A Butman; Robert Wesley; Raphaela Goldbach-Mansky
Journal:  Arthritis Rheum       Date:  2012-07

3.  Fine specificities of natural regulatory T cells after IVIG therapy in patients with Kawasaki disease.

Authors:  Jane C Burns; Ranim Touma; Yali Song; Robert L Padilla; Adriana H Tremoulet; John Sidney; Alessandro Sette; Alessandra Franco
Journal:  Autoimmunity       Date:  2015-03-30       Impact factor: 2.815

4.  Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.

Authors:  Jane W Newburger; Lynn A Sleeper; Brian W McCrindle; L LuAnn Minich; Welton Gersony; Victoria L Vetter; Andrew M Atz; Jennifer S Li; Masato Takahashi; Annette L Baker; Steven D Colan; Paul D Mitchell; Gloria L Klein; Robert P Sundel
Journal:  N Engl J Med       Date:  2007-02-15       Impact factor: 91.245

5.  Infliximab as a novel therapy for refractory Kawasaki disease.

Authors:  Jennifer E Weiss; B Anne Eberhard; Devyani Chowdhury; Beth S Gottlieb
Journal:  J Rheumatol       Date:  2004-04       Impact factor: 4.666

6.  2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications.

Authors:  Sarah Ringold; Pamela F Weiss; Timothy Beukelman; Esi Morgan DeWitt; Norman T Ilowite; Yukiko Kimura; Ronald M Laxer; Daniel J Lovell; Peter A Nigrovic; Angela Byun Robinson; Richard K Vehe
Journal:  Arthritis Rheum       Date:  2013-10

7.  A functional polymorphism, rs28493229, in ITPKC and risk of Kawasaki disease: an integrated meta-analysis.

Authors:  Jiao Lou; Sanqing Xu; Li Zou; Rong Zhong; Ti Zhang; Yu Sun; Xuzai Lu; Li Liu; Chuanqi Li; Li Wang; Guanglian Xiong; Wei Wang; Fangqi Gong; Jing Wu
Journal:  Mol Biol Rep       Date:  2012-10-13       Impact factor: 2.316

8.  Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.

Authors:  Adriana H Tremoulet; Sonia Jain; Preeti Jaggi; Susan Jimenez-Fernandez; Joan M Pancheri; Xiaoying Sun; John T Kanegaye; John P Kovalchin; Beth F Printz; Octavio Ramilo; Jane C Burns
Journal:  Lancet       Date:  2014-02-24       Impact factor: 79.321

9.  Use of canakinumab in the cryopyrin-associated periodic syndrome.

Authors:  Helen J Lachmann; Isabelle Kone-Paut; Jasmin B Kuemmerle-Deschner; Kieron S Leslie; Eric Hachulla; Pierre Quartier; Xavier Gitton; Albert Widmer; Neha Patel; Philip N Hawkins
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

10.  Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases.

Authors:  A Suzuki; T Kamiya; N Kuwahara; Y Ono; T Kohata; O Takahashi; K Kimura; M Takamiya
Journal:  Pediatr Cardiol       Date:  1986       Impact factor: 1.655
View more
  24 in total

1.  Myocardial fibrosis after adrenergic stimulation as a long-term sequela in a mouse model of Kawasaki disease vasculitis.

Authors:  Harry H Matundan; Jon Sin; Magali Noval Rivas; Michael C Fishbein; Thomas J Lehman; Shuang Chen; Roberta A Gottlieb; Timothy R Crother; Masanori Abe; Moshe Arditi
Journal:  JCI Insight       Date:  2019-02-07

2.  NLRP3 Inflammasome Mediates Immune-Stromal Interactions in Vasculitis.

Authors:  Rebecca A Porritt; David Zemmour; Masanori Abe; Moshe Arditi; Magali Noval Rivas; Youngho Lee; Meena Narayanan; Thacyana T Carvalho; Angela C Gomez; Daisy Martinon; Chintda Santiskulvong; Michael C Fishbein; Shuang Chen; Timothy R Crother; Kenichi Shimada
Journal:  Circ Res       Date:  2021-09-14       Impact factor: 23.213

3.  High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant.

Authors:  Marie Lind-Holst; Ulla Birgitte Hartling; Anne Estmann Christensen
Journal:  BMJ Case Rep       Date:  2019-08-04

4.  A comparison of the predictive validity of the combination of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and other risk scoring systems for intravenous immunoglobulin (ivig)-resistance in Kawasaki disease.

Authors:  Seiichiro Takeshita; Takashi Kanai; Yoichi Kawamura; Yusuke Yoshida; Shigeaki Nonoyama
Journal:  PLoS One       Date:  2017-05-23       Impact factor: 3.240

Review 5.  Dissecting Kawasaki disease: a state-of-the-art review.

Authors:  S M Dietz; D van Stijn; D Burgner; M Levin; I M Kuipers; B A Hutten; T W Kuijpers
Journal:  Eur J Pediatr       Date:  2017-06-27       Impact factor: 3.183

Review 6.  IL-1 Inhibition May Have an Important Role in Treating Refractory Kawasaki Disease.

Authors:  Perrine Dusser; Isabelle Koné-Paut
Journal:  Front Pharmacol       Date:  2017-03-28       Impact factor: 5.810

7.  Innate immune responses following Kawasaki disease and toxic shock syndrome.

Authors:  Katherine Y H Chen; Nicole Messina; Susie Germano; Rhian Bonnici; Bridget Freyne; Michael Cheung; Greta Goldsmith; Tobias R Kollmann; Michael Levin; David Burgner; Nigel Curtis
Journal:  PLoS One       Date:  2018-02-15       Impact factor: 3.240

8.  Platelets Fuel the Inflammasome Activation of Innate Immune Cells.

Authors:  Verena Rolfes; Lucas Secchim Ribeiro; Ibrahim Hawwari; Lisa Böttcher; Nathalia Rosero; Salie Maasewerd; Marina Lima Silva Santos; Tomasz Próchnicki; Camila Meirelles de Souza Silva; Carlos Wagner de Souza Wanderley; Maximilian Rothe; Susanne V Schmidt; H James Stunden; Damien Bertheloot; Magali Noval Rivas; Cor Jesus Fontes; Luzia Helena Carvalho; Fernando Queiroz Cunha; Eicke Latz; Moshe Arditi; Bernardo Simoes Franklin
Journal:  Cell Rep       Date:  2020-05-12       Impact factor: 9.423

9.  Interleukin-1 pathway in active large vessel vasculitis patients with a poor prognosis: a longitudinal transcriptome analysis.

Authors:  Kotaro Matsumoto; Katsuya Suzuki; Keiko Yoshimoto; Sho Ishigaki; Hiroto Yoshida; Mayu Magi; Yoshihiro Matsumoto; Yuko Kaneko; Tsutomu Takeuchi
Journal:  Clin Transl Immunology       Date:  2021-07-02

10.  Predictive model based on gene and laboratory data for intravenous immunoglobulin resistance in Kawasaki disease in a Chinese population.

Authors:  Li Meng; Zhen Zhen; Xiao-Hui Li; Yue Yuan; Qian Jiang; Wei Yao; Ming-Ming Zhang; Ai-Jie Li; Lin Shi
Journal:  Pediatr Rheumatol Online J       Date:  2021-06-26       Impact factor: 3.054
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.